The presence of CKD in the context of GLP-1 agonist research is noteworthy, given the established cardiovascular benefits of these agents in individuals with type 2 diabetes, a common precursor to both CKD and cardiovascular diseases90–92. Here, GCG is linked to chronic kidney disease.